SREBF1 and cancer: Importantly, regulation of the PPP by AR-SREBP1-6PGD has a broader clinical implication; therapeutic strategies that effectively suppress this pathway would impinge on the activity of three important oncogenic drivers with multifaceted cancer-promoting activities.